Head to head

[bromley]

The following story is from the Boston Cure Project today.

One has to agree with Art's comment at the end.

Ian

"A two year open-label study comparing Betaseron (called Betaferon in Europe) and Avonex found no substantial differences in relapse rates, time to first relapse, progression of disability, and neutralizing antibody development".

Can we stop spending money on studies of the existing drugs and start looking at some new ones, now?"

[HarryZ]

Ian,

Can we stop spending money on studies of the existing drugs and start looking at some new ones, now?"

These companies have no interest in getting into the deep research required in finding a cause for MS and thus possibly a cure. The ONLY reason you see them doing these head to head trials is to attempt to gain a few percent increase in the market share of the current "approved" therapies for MS. Just a few percent gain means millions in increased revenue. This is strictly business and has little if anything to do with the health concern of MS patients.

Harry